Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer
Adam Kraya(Translational Therapeutics (United States)), Katherine L. Nathanson(Translational Therapeutics (United States)), Michael D. Feldman(University of Pennsylvania), Jennifer J.D. Morrissette(University of Pennsylvania), Nandita Mitra(University of Pennsylvania), Robert H. Vonderheide(University of Pennsylvania), Andrew J. Rech(Parker Institute for Cancer Immunotherapy), Bradley Wubbenhorst(Translational Therapeutics (United States)), Kara N. Maxwell(Philadelphia VA Medical Center), Susan M. Domchek(University City Science Center), Anupma Nayak(University of Pennsylvania), Brandon M. Wenz(Translational Therapeutics (United States)), Amanda Barrett(University of Pennsylvania), Nicole Lunceford(University of Pennsylvania), John Pluta(Translational Therapeutics (United States)), Liza M. Dorfman(Translational Therapeutics (United States))
Cited by 103
Related Papers
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
Network modeling links breast cancer susceptibility and centrosome dysfunction
|Nature Genetics|2007|634